Category Archives: BioUtah News
Civica to Manufacture and Distribute Affordable Insulin
Americans with diabetes will have access to more affordable insulins through a transparent, cost-plus model
MDMA Urgent Request: Medical Supplies for Ukraine Needed
MDMA Urgent Request: Medical Supplies for Ukraine Needed
ARUP Renames Consulting Team as ARUP Healthcare Advisory Services
ARUP Laboratories has renamed its expert team of healthcare consultants as ARUP Healthcare Advisory Services.
TRIA Transcatheter Biopolymer Heart Valve Shows Promise in Pilot Animal Study
Foldax announced the presentation of results from the first animal study of its transcatheter valve from the TRIA™ biopolymer heart valve portfolio
Rare Disease Week
BioUtah is pleased to recognize Rare Disease Day, designated as February 28. There are approximately 7,000 rare diseases, affecting an estimated 25 million to 30 million Americans. Only five percent of these diseases have a treatment. The mantra of the National Organization for Rare Disorders (NORD) – “Alone we are rare. Together we are strong” […]
BD Appoints Shana Neal as Chief People Officer
BD announced that Shana Neal has been appointed chief people officer.
Volunteer Opportunities for Weber County STEM events
Volunteers Needed for Weber County STEM events
Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
Myriad Genetics announced financial results for its fourth quarter and year ended Dec. 31, 2021.
SINTX ANNOUNCES MILESTONES IN THE DEVELOPMENT AND TESTING OF ANTIPATHOGENIC FABRICS
SINTX Technologies announced new results on the development of manufacturing technologies to produce fabrics impregnated with SINTX silicon nitride, and the antipathogenic testing of these fabrics.
Renalytix to Appoint Timothy Scannell to Board of Directors
Renalytix announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director.
SkinTE® Met Primary and Secondary Endpoints in Multicenter, Randomized Controlled Trial in Venous Leg Ulcers
PolarityTE announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers (VLU) with its investigational product SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881267).
